Ignite Creation Date:
2024-05-06 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 2:12 PM
Study NCT ID:
NCT05032157
Status:
COMPLETED
Last Update Posted:
2024-07-05
First Post:
2021-08-19
Brief Title:
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1- Antihistamines
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Chronic Spontaneous Urticaria |
Keywords:
| Name | View |
|---|---|
| Weekly Hives Severity Score HSS7 | View |
| Bruton Tyrosine Kinase BTK inhibitor | View |
| Chronic Spontaneous Urticaria CSU | View |
| Urticaria Activity Score UAS | View |
| Weekly Urticaria Activity Score UAS7 | View |
| Hives Severity Score HSS | View |
| Itch Severity Score ISS | View |
| Weekly Itch Severity Score ISS7 | View |
| Angioedema Activity Score AAS | View |
| Weekly Angioedema Activity Score AAS7 | View |
| Dermatology Life Quality Index DLQI | View |